The Oxford COVID-19 vaccine has been proven 100% effective at preventing serious disease, as a new trial involving 32,000 volunteers has shown…
The highly-anticipated results from the major trial of the jab in the US have also proven it safe to use and 79% effective against symptomatic coronavirus. Volunteers were given two doses, four weeks apart, and a fifth of them were over the age of 65, marking them as the most at risk of serious illness.
141 cases of COVID-19 were reported among all the trialists, but none were taken to the hospital. Among those over 65, 80% protection was found against COVID-19. The degree of the jab’s effectiveness was ultimately even greater than observed in the Oxford-led clinical trials.
The lead investigator behind the Oxford University trial, Andrew Pollard explains, ‘These results are great news as they show the remarkable efficacy of the vaccine in a new population and are consistent with the results from Oxford-led trials’. We can expect strong impact against Covid-19 across all ages and for people of all different backgrounds from widespread us of the vaccine.’
This comes after days of speculations that it causes blood clots, with 13 European countries suspending its use. However, such findings strongly endorse the use of the vaccine and reassure its safety.
After the European Medicines Agency concluded it didn’t raise the overall risk of blood clots, most countries have now resumed the vaccine’s rollout. Meanwhile, in the US, the trial looked at the risks of cerebral venous sinus thrombosis (CVST) – the brain blood clot that has been troubling the EU.
The US trial found no increased risk of thrombosis and no cases of CVST were identified. Sarah Gilbert from the Oxford trial also confirmed that the jab is still effective in older people too, ‘It was just as good in the over-65s as it was in the younger people and that’s very clear from this trial.’, she added.
AstraZeneca is now expected to submit data to the US Food and Drug Administration (FDA) and seek emergency approval for use.